Chlorpromazine versus atypical antipsychotic drugs for schizophrenia

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 4, 2016, Pages

  Saha, Kumar B ^a   Bo, Li ^b   Zhao, Sai ^c   Xia, Jun ^d   Sampson, Stephanie ^d   Zaman, Rashid U ^e  

^a LEEDS AND YORK PARTNERSHIP NHS FOUNDATION TRUST   (United Kingdom)

^b XIYUAN HOSPITAL   (China)

^c Systematic Review Solutions Ltd   (China)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^e Oxford Policy Management   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHLORPROMAZINE; HUMANS; QUETIAPINE FUMARATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISPERIDONE; SCHIZOPHRENIA;

EID: 84979097046     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010631.pub2     Document Type: Review

References (227)

1. Dossenbach M. Sleep quality and early morning wakefulness of schizophrenic patients treated with olanzapine compared to chlorpromazine. European Neuropsychopharmacology 2000;10(Supplement 3):S328-9.
2. Eli Lilly, Company. Study F1D-VI-HGCQ olanzapine versus chlorpromazine in Turkey. Unpublished document internal to Eli-Lilly 2000:1-560.
3. Kostakoglu E, Alptekin K, Kivicik BB, Martenyi F, Tunca Z, Gogus A, et al. Sleep quality and early morning wakefulness of schizophrenia patients treated with olanzapine compared to chlorpromazine [Errata]. European Neuropsychopharmacology 2001;11(Suppl 3):S369.
4. Mraz K, Gogus A, Tunca Z, Martenyi F, Dossenbach M. Olanzapine versus chlorpromazine in Turkey. Schizophrenia Research (Abstracts of the Winter Workshop on Schizophrenia; February 5-11, 2000; Davos, Switzerland). 2000.
5. Eli Lilly, Company. Study HGDV olanzapine (versus chlorpromazine in Morocco). Unpublished document internal to Eli-Lilly and Company 2001:1-512.
6. HGDV/Morocco. Data supplied to the Cochrane Schizophrenia Group. Data on file 1999.
7. An BF, Li Y, Wang CH. Olanzapine on effect of executive dysfunction in schizophrenia. Journal of Clinical Psychiatry 2006;16(3):144-5.
8. Chang FW, Wang CH, Zhao Z. Clinical effects of olanzapine vs chlorpromazine in treating positive symptoms of schizophrenia. Chinese Journal of New Drugs and Clinical Remedies 2003;22(6):357-9.
9. Chen F. Olanzapine and chlorpromazine in the treatment of schizophrenia. Journal of Clinical Psychiatric Medicine 2006;16:303-4.
10. He J, An Q. A comparative trial of olanzapine versus chlorpromazine in the treatment of schizophrenia. Shandong Mental Health Archive 2003;16:78-80.
11. Eli Lilly, Company. HGDT olanzapine versus chlorpromazine in Egypt. Unpublished document internal to Eli Lilly and Company 2001:1-513.
12. Loza N, El-Dosoky AM, Okasha TA, Khalil AH, Hasan NM, Dossenbach M, et al. Olanzapine compared to chlorpromazine in acute schizophrenia. European Neuropsychopharmacology 1999;9(Suppl 5):S291.
13. Luo C, Yang JW, Ren JP. Comparative study of the effect of olanzapine on serum lipid in schizophrenia. Journal of Clinical Psychiatric Medicine 2007;17:401-2.
14. Wang CH, Zhao Z, Li Y, Pan M, Liu X. Evaluation of proximal therapeutic effect and distal social function restoration of olanzapine on schizophrenia patients. Zhongguo lin chuang kang fu [Chinese Journal of Clinical Rehabilitation] 2002;6(17):2664-5.
15. Wang Q, Li L, Wang T. A comparative study of olanzapine in treatment of schizophrenia. Journal of Psychiatry 2008;21:373-5.
16. Wu Y, Lu WH, Yi ZH, Wang J, Song BF, Shi DQ, et al. Controlled study of olanzapine versus chlorpromazine for the quality of life of patients with schizophrenia. Sichuan Mental Health Journal 2008;21(1):8-11.
17. Zhao Z, Yan F, Feng Y. A comparative study on olanzapine and chlorpromazine in the treatment of schizophrenia. China Journal of Health Psychology 2006;14:41-2.
18. Ai L. A comparative study of efficacy and safety of seroquel versus chlorpromazine in the treatment of schizophrenia. Heilongjiang Medical Journal 2007;31(4):285.
19. An QH, Hu KY, Meng XL. A comparison of intelligence disorders and memory disorders in the first-onset schizophrenia treated with quetiapine and chlorpromazine. Chinese Journal of Behavioral Medical Science 2005;14(1):62-3.
20. Cai DM. Clinical comparative study of quetiapine and chlorpromazine in the treatment of schizophrenia. Medical Journal of Chinese People's Health 2006;18(4):281-2.
21. Cai Q, Wang Z, Lin Y, Zhang X. Quetiapine and chlorpromazine in the treatment of schizophrenia: a random, controlled trial. Shanghai Archives of Psychiatry 2007;19(1):12-4.
22. Cao D, Xie SP, Chen QB, Yuan YG, Fang Q. Characteristics of the sexual disturbance caused by chlorpromazine, risperidone, quetiapine and olanzapine and their associations with the changes of blood glucose and blood lipids in male patients with schizophrenia. Chinese Journal of Clinical Rehabilitation [Zhongguo Lin Chuang Kang Fu] 2005;9(36):63-8.
23. Chen J, Zhao J, Li L. Multi-center, double blind control study of domestic manufactured quetiapine on schizophrenia. Chinese Journal of Psychiatry 2001;34(4):193-6.
24. Zhao JP, Chen JD, Chen YG, Shu L, Ma C. A double-blind and double-dummy comparative study of quetiapine and chlorpromazine in the treatment of schizophrenia. Chinese New Drugs Journal 2002;11(2):149-51.
25. Chen F, Chen Y, Zhou B, Cheng F, Liu Y, Zho XW, et al. Quetiapine treatment in schizophrenia curative effect and quality of life. Journal of Clinical Psychiatry [Linchuang Jingshen Yixue Zazhi] 2007;17(5):319-20.
26. Chen S. Quetiapine and chlorpromazine in the treatment of schizophrenia. Medical Journal of Chinese People's Health 2008;20(7):660.
27. Cheng XF. Control observation of quetiapine vs chlorpromazine in schizophrenia. Journal of Clinical Psychosomatic Diseases 2003;9(2):78-80.
28. Deng YF, Liu CY, Liu ZR, Zhang W. 利培酮合用氯硝西泮治疗精神分裂症急性期兴奋状态疗效观察. 中国实用内科杂志 2004;24:496-7.
29. Guo BY, Wang YB. Control studies on efficacy of quetiapine vs chlorpromazine in first - episode schizophrenics. Journal of Clinical Psychosomatic Diseases 2003;9(2):75-7.
30. Guo P, Guo H, Yang C. A comparative study on the effects of quetiapine and chlorpromazine upon the life quality of patients with schizophrenia. Nervous Diseases and Mental Hygiene 2003;3(6):454-5.
31. Guo HR, Song SY. Domestic quetiapine and chlorpromazine in the treatment of schizophrenia in controlled clinical studies. Modern Journal of Integrated Traditional Chinese and Western Medicine 2005;14:443-4.
32. Guo XF, Zhao JP, Chen JD, Zhang ZC. The effect of chlorpromazine and quetiapine on serum lipid and glucose. Journal of Clinical Psychiatry 2006;16(5):257-9.
33. Guo J, Cao C, Wu D. Effect of quetiapine and chlorpromazine on cognitive function in first-episode schizophrenic. Chinese Journal of Health Psychology 2007;15(7):583-4.
34. Guo Z, Liu J, Yang J. Efficacy quetiapine in the treatment of schizophrenic patients and effect on the quality of life. Chinese Journal of Health Psychology 2008;16(5):544-6.
35. He YD, Zhao CM, Shao AL, Chen YN. A comparative study of quetiapine and chlorpromazine in the treatment of patients with schizophrenia. Herald of Medicine 2003;22(10):680-2.
36. Hu JM, Li Yi, Li Tao, Wang HM, Liu XH, Huo KJ. The effects of antipsychotics on serum prolactin in the first-episode schizophrenia patients. West China Journal of Pharmaceutical Sciences 2003;18(6):467-9.
37. Ji J, Ou W. Comparative study between the quality of life and its curative effect in schizophrenic patients treated with quetiapine or chlorpromazine. Sichuan Mental Health 2004;17(2):73-5.
38. Jiang KD, Bai YL, Peng DH, Tang MQ, Fan JX, Ma JS. A random and controlled study of quetiapine and chlorpromazine in patients with schizophrenia. Journal of Clinical Psychiatry [Linchuang Jingshen Yixue Zazhi] 2006;16(6):352-3.
39. Jiang GQ, Luo J. A controlled study of quetiapine and chlorpromazine for schizophrenia. Chongqing Journal of Medicine 2008;37(16):1835-6.
40. Jin S, Liu S, Sang W, Zhao M. Seroquel and chlorpromazine in treatment of schizophrenia: a random, controlled trial. China Pharmaceuticals 2007;16(19):56-7.
41. Kong DL, Zhang SQ, Shu MQ. Effects of quetiapine and chlorpromazine on serum prolactin of schizophrenics. Journal of Clinical Psychosomatic Diseases 2003;9(4):200-1.
42. Li M, Hu F, Wang S. A study of quetiapine and chlorpromazine on the effects and quality of life in the treatment of schizophrenia. Shandong Archives of Psychiatry 2003;16(3):135-7.
43. Li YQ, Zhuang JH. Quetiapine and chlorpromazine in the treatment of schizophrenia with depression. Journal of Qiqi ha-er Medical College 2010;31(3):395.
44. Liu SF, Qin X. Quetiapine for late onset schizophrenia. Shandong Archive of Psychiatry 2003;16(3):164.
45. Mei AC. Comparison of efficacy and safety of quetiapine and chlorpromazine in the treatment of schizophrenia. Medical Journal of Chinese People's Health 2007;19(17):723-4.
46. Nai X, Hu X, Qiu S. Effect of quetiapine on cognition function of patients with first episode schizophrenia. Journal of Medical Forum 2007;28(2):38-9.
47. NCT00882518. Efficacy and safety of quetiapine fumarate in the treatment of schizophrenic patients. http://www.clinicaltrials.gov (accessed 28 February 2012).
48. Peng ZG, Zhou JX, Kuang WH, Li J, Huang MS. A randomized double - blind controlled study on the efficacy of quetiapine and chlorpromazine in treatment of schizophrenia. West China Journal of Pharmaceutical Sciences 2006;21(6):606-8.
49. Peuskens J, Link CGG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatrica Scandinavica 1997;96(4):265-73.
50. Sun XD, Zhou SB, Li ZM, Han ZF. Effect of cognitive function in first-episode schizophrenia treated with quetiapine. Journal of Clinical Psychiatry 2006;16(2):94-5.
51. Tian H, He Q, Du L, Wu R, Hui S, Zheng Q, et al. Comparative study on the effect of seroquel and chlorpromazine on schizophrenia. China Pharmacy 2006;17(9):682-3.
52. Wan C, Lan SZ, Zhu XJ, Liao B, Wan J. A double blind controlled study of quetiapine and chlorpromazine for schizophrenia. Journal of Yichun University 2002;24(2):55-6.
53. Wan ZY, Mei HB. A controlled study of quetiapine and chlorpromazine for schizophrenia. Medical Journal of Chinese People's Health 2008;20(11):1151-3.
54. Wang XL, Jiang F, Li T. Comparison of efficacy and safety of quetiapine and larctigal in the treatment of schizophrenia. Chinese Journal of Behavioral Medical Science 2004;13(3):288-90.
55. Wang H, Peng D, Bai Y. Efficacy of quetiapine in the treatment of female patients with schizophrenia. Shanghai Archives of Psychiatry 2005;17(2):83-6.
56. Yang L, Yuan YG. Quetiapine and chlorpromazine in the treatment of people with schizophrenia. Medical Journal of Chinese People's Health 2007;19(12):1050-1.
57. Zhang S, Li Y, Xu J. A double-blind study of domestic quetiapine and chlorpromazine in the treatment of schizophrenia. Shandong Archives of Psychiatry 2002;15(3):149-51.
58. Zhang HY, Wang X, Liu C, Shu L, Li H, Gu N, et al. A comparison study on efficacy and safety of quetiapine and chlorpromazine in the treatment of schizophrenia. Chinese Journal of Clinical Pharmacology 2003;19(3):163-6.
59. Ma J. Quetiapine and chlorpromazine in the treatment of first-episode schizophrenia controlled clinical studies. Chinese Clinical Practical Medicine 2007; Vol. 1, issue 2:51-2.
60. Ma J. Quetiapine and chlorpromazine in the treatment of first-episode schizophrenia controlled clinical studies. Journal of Qiqihar Medical College [Qiqihar Yixueyuan Xuebao] 2007;28(9):1038-9.
61. Zhang W, Ma JG, Xu FL. Comparison study on treatment of primary schizophrenia with quetiapine and chlorpromazine. Heilongjiang Nursing Journal [Modern Nursing] 2006;30(2):81-2.
62. Zhang J. A controlled study of quetiapine and chlorpromazine for schizophrenia. Neurological Disorders and Mental Health 2008;8(2):149-50.
63. Zhou J, Li J, Kuang W. Comparison between quetiapine and chlorpromazine in cognitive function of schizophrenic patients. Chinese Mental Health Journal 2003;17(10):699-701.
64. Zhou SB, Sun XD, Li YM. A comparative study on quetiapine and chlorpromazine in the treatment of schizophrenia. Medical Journal of Chinese People's Health 2004;16(11):657-9.
65. Zou X, Zhou Y, Zhang W. Study on quetiapine and chlorpromazine in treatment of schizophrenia. China Pharmaceuticals 2006;15(12):51-2.
66. Chang SL, Wang GH. Clinical observation of risperidone and chlorpromazine in the treatment of schizophrenia. Anhui Medical and Pharmaceutical Journal 1998; Vol. 2:25-6.
67. Cui L. Risperidone and chlorpromazine in the treatment of schizophrenia, double-blind, controlled study, and serum prolactin efficacy. Hebei Archive of Psychiatry 2001;14:205-8.
68. Feng YX, Sun F. A comparative study on the effects of risperidone and chlorpromazine upon the life quality of patients with schizophrenia. Health Psychology Journal 2003;11:117-8.
69. He M, Feng Y, Chen R. A controlled comparative study on risperidone and chlorpromazine in treatment of schizophrenia. Chinese New Drugs Journal 1999;8:185-7.
70. Lin WX. Risperidone and chlorpromazine in the treatment of clinical controlled study of 70 patients with schizophrenia. Modern Chinese Practical Medicine Journal 2005;4:27-8.
71. Liu Y, Huang X, Xie L. A comparative study of risperidone and chlorpromazine in the treatment of the negative symptoms of schizophrenia. Journal of Medicine and Pharmacy 2000;19:323-4.
72. Liu GR, Zhang YH. Risperidone and chlorpromazine on schizophrenia blood pressure, heart rate. Occupation and Health 2005;21:443-5.
73. Luo X, Jiang K, Gu N, Yang X, Zhu S. Comparison of effects and factors between risperidone and chlorpromazine on schizophrenia. Chinese Journal of New Drugs and Clinical Remedies 2001;20:264-6.
74. Ma Z H, Liu A Y, Zhou C M, Zhang Z. A comparative study of risperidone and chlorpromazine in the treatment of schizophrenia. Medical Journal of Chinese People Health 2004;16:202-4.
75. Wang Q, Jia C. Controlled study of risperidone and chlorpromazine in the treatment of schizophrenia. Health Psychology Journal 2002;10:226-8.
76. Wang X, Hu X, Yang J. Effect of chlorpromazine and risperidone on cognitive function of the patients with first episode schizophrenia. Chinese Journal of Health Psychology 2005;13:342-4.
77. Wu S, Xing G. A comparative trial on the efficacy of risperidone vs chlorpromazine in chronic schizophrenia. Health Psychology Journal 2002;10:364-5.
78. Wu Y, Lu W, Yi Z. A comparative study of risperidone and chlorpromazine on quality of life in patients with schizophrenia. Shandong Archive of Psychiatry 2004;17:137-40.
79. Zheng ZS, Huang JM, Yu XY. Efficacy of risperidone and chlorpromazine in the treatment of schizophrenia. Chinese Hospital Pharmacy Journal 2001;21:99-100.
80. Appelberg B, Sintonen H, Tuisku K, Joffe G. Is it worthwhile to change clinically stable schizophrenic outpatients with mild to moderate residual symptoms and/or side effects from conventional to atypical antipsychotics? – a randomised study with olanzapine. Proceedings of the 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7-13; Davos, Switzerland. 2004.
81. Appelberg B, Tuisku K, Joffe G. Is it worth while changing clinically stable schizophrenic out-patients with mild to moderate residual symptoms and/or side effects from conventional to atypical antipsychotics? A prospective, randomised study with olanzapine. European Psychiatry 2004;19(8):516-8.
82. Appelberg B, Tuisku K, Joffe G. Is it worthwhile changing clinically stable schizophrenic out-patients with mild to moderate residual symptoms and/or side effects from conventional to atypical antipsychotics?. Schizophrenia Research 2004;67(1):140-1.
83. Joffe G, Sintonen H, Appelberg B. Shift from first generation antipsychotics to olanzapine may improve health-related quality of life of stable but residually symptomatic schizophrenic outpatients: a prospective, randomized study. International Journal of Technology Assessment in Health Care 2008;24(4):399-402.
84. Beasley CM, Beuzen JN, Birkett MA. [Olanzapine versus clozapine: an international double-blind study in the treatment of patients with treatment-resistent schizophrenia]. New Clinical Drug Evaluation Unit (NCDEU) Meeting; 1999 June 12-15; Boca Raton, FL, USA. 1999.
85. Beasley CM, Beuzen JN, Birkett MA. Olanzapine versus clozapine: an international double-blind study in the treatment of patients with treatment-resistent schizophrenia. American College of Neuropsychopharmacology Annual Meeting. Hawaii, 1998.
86. Beasley CM, Beuzen JN, Birkett MA. Olanzapine versus clozapine: an international double-blind study in the treatment of patients with treatment-resistent schizophrenia. American Psychiatric Association Meeting; 1999 January 31 - February 2; Washington, DC, USA. 1999.
87. Beasley CM, Beuzen JN, Birkett MA. Olanzapine versus clozapine: an international double-blind study in the treatment of patients with treatment-resistent schizophrenia. World Psychiatric Association; 1999 August 6-11; Hamburg, Germany. 1999.
88. Beuzen JN, Birkett M, Kiesler G, Wood A. Olanzapine versus clozapine in resistant schizophrenic patients - results of an international double-blind randomised clinical trial. Proceedings of XXIst Collegium Internationale Neuro-psychopharmacologicum; 1998 July 12-16; Glasgow, UK. 1998.
89. Beuzen JN, Birkett MA, Kiesler GM. An investigation of subgroup effects in a study of olanzapine versus clozapine in the treatment of resistant schizophrenic patients. European Neuropsychopharmacology 1998;8(Suppl 2):S226-7.
90. David SR, Meehan KM, Sutton VK, Taylor CC. Treatment of negative symptoms with olanzapine in comparison with other novel antipsychotic agents. International Journal of Neuropsychopharmacology 2000;3(Suppl 1):S140.
91. Dossenbach M, Bitter I, Slabber M, Pretorius J, Bartko GY, Banics Z, et al. Olanzapine versus clozapine in patients nonresponsive or intolerant to standard acceptable treatment for schizophrenia. 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, USA. 2000.
92. Dossenbach M, Bitter I, Slabber M, Pretorius J, Bartko GY, Banics Z, et al. Olanzapine versus clozapine in patients nonresponsive or intolerant to standard acceptable treatment for schizophrenia. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA. 2002.
93. Dossenbach M, Slabber M, Martenyi F, Bartko G, Bitter I. Olanzapine vs. clozapine in patients non responsive or intolerant to standard acceptable treatment of schizophrenia. 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany. 1999:148.
94. Jean-Noel B, Wood AJ, Kiesler GM, Birkett M, Tollefson GD. Olanzapine vs. clozapine: an international double blind study in the treatment of resistant schizophrenia. 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany. 1999:143.
95. Tollefson GD, Birkett MA, Kiesler GM, Wood AJ, Lilly Resistant Schizophrenia Study Group. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biological Psychiatry 2001;49(1):52-63.
96. Bouchard RH. A comparative longitudinal study of risperidone versus classic neuroleptic drugs in the treatment of schizophrenia: 24 months observation. Journal of Clinical Psychopharmacology 2002;28:31-2.
97. Bouchard RH, Demers MF, Merette E, Pourcher E. Classical neuroleptics (CNLP) vs risperidone (RIS) interim 12 months efficacy analysis of a long-term, naturalistic study in schizophrenia. 21st Congress of the Collegium Internationale Neuro-Psychopharmacologicum (CINP); 1998 Jul 12-16; Glassgow, UK. 1998.
98. Bouchard RH, Merette C, Demers MF, Roy-Gagnon MH. Risperidone versus classical neuroleptics: preliminary results of a prospective naturalistic one year study. 151st Annual Meeting of the American Psychiatric Association; 1998 May 30-Jun 4; Toronto. Toronto, Canada, 1998:180.
99. Bouchard RH, Mérette C, Pourcher E, Demers MF, Villeneuve J, Roy Gagnon MH, et al. Longitudinal comparative study of risperidone and conventional neuroleptics for treating patients with schizophrenia. The Quebec Schizophrenia Study Group. Journal of Clinical Psychopharmacology 2000;20(3):295-304.
100. Bouchard RH, Pourcher E, Merette C, Demers MF, Villeneuve J, Roy Gagnon MH, et al. One-year follow-up of schizophrenic patients treated with risperidone or classical neuroleptics: a prospective, randomized, multicentred open-study. 11th Congress of the European College of Neuropsychoharmacology; 1998 Oct 31- Nov 4; Paris, France. 1998.
101. Bouchard RH, Pourcher E, Merette C, Demers MF, Villeneuve J, Roy MA, et al. Risperidone advantages in chronic schizophrenic patients: a 1-year effectiveness study. Schizophrenia Research 1999;36(1-3):271.
102. Chen GY, Li B, Li C. Clinical observation on schizophrenic patients treated with risperidone. Journal of Clinical Psychiatry 2001;11:325-8.
103. Conley R, Gounaris C. Demographic differences in olanzapine responders with therapy-refractory schizophrenia. Schizophrenia Research the VIth International Congress on Schizophrenia Research;1997 April 12-16; Colorado Springs, CO. 1997; Vol. 24 Suppl:189.
104. Conley RR, Tamminga CA, Bartko JJ, Richardson C, Peszke M, Lingle J, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. American Journal of Psychiatry 1998;155(7):914-20.
105. Conley RR, Tamminga CA, Beasley C. Olanzapine vs chlorpromazine in therapy-refractory schizophrenia. Schizophrenia Research, The VIth International Congress on Schizophrenia Research; 1997 April 12-16; Colorado Springs, CO. 1997; Vol. 24 Suppl:189.
106. Conley RR, Tamminga CA, Beasley C. Olanzapine vs. chlorpromazine in treatment-resistant schizophrenia. Biological Psychiatry 1997;41:1S-120S.
107. Conley RR, Tamminga CA, Beasley C, Maryland Study Group. Olanzapine vs. chlorpromazine in treatment-resistant schizophrenia. Biological Psychiatry 1997;41:73S.
108. Kelly DL, Conley RR, Tamminga CA. Differential olanzapine plasma concentrations by sex in a fixed-dose study. Schizophrenia Research 1999;40(2):101-4. [CSG NO. 4333]
109. Richardson C, Conley R. Olanzapine response in schizophrenic subjects with neuroleptic resistant disorganization. Schizophrenia Research, The VIth International Congress on Schizophrenia Research; 1997 April 12-16; Colorado Springs, CO. 1997; Vol. 24 Suppl:191.
110. Czekalla J, Beasley CM Jr, Dellva MA, Berg PH, Grundy S. Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. Journal of Clinical Psychiatry 2001;62(3):191-8.
111. de Jesus Mari J, Lima MS, Costa AN, Alexandrino N, Rodrigues-Filho S, de Oliveira IR, et al. The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders. European Archives of Psychiatry and Clinical Neuroscience 2004;254(6):356-61.
112. David SR, Meehan KM, Sutton VK, Taylor CC. Treatment of negative symptoms with olanzapine in comparison with other novel antipsychotic agents. International Journal of Neuropsychopharmacology 2000;3(Suppl 1):S140.
113. Edgell ET, Andersen SW, Grainger D, Wang J. Resource use and quality of life of olanzapine compared with risperidone: results from an international randomized clinical trial. XXIst Collegium Internationale Neuro-psychopharmacologicum; 1998, July 12-16; Glasgow, UK. 1998.
114. Feng CX, Huang SX, Yang HZ. A comparative trial on the efficacy of risperidone vs chlorpromazine in treatment-resistant schizophrenia. Shandong Archive of Psychiatry 2001;14:95-6.
115. Hu TS. Comparative analysis of the positive symptoms of schizophrenia treated with risperidone. Chinese Journal of Behavioral Medical Science 2005;14:428.
116. Huang SX, Feng CX, Chen JY, Liu DQ. Risperidone vs chlorpromazine in treating schizophrenia: a randomized double-blind study. Chinese Journal of New Drugs and Clinical Remedies 2000;19:396-8.
117. Huang YH, Luo BM. Risperidone and chlorpromazine, clozapine drug-control study. Chinese Journal of New Drugs and Clinical Remedies 2000;8:210-1.
118. Kostakoglu E, Alptekin K, Kivircik BB, Dossenbach M, Tunca Z, Gogus A. Olanzapine vs. chlorpromazine- 6 weeks treatment of acute schizophrenia. Journal of European College of Neuropsychopharmacology 2001;11:S369.
119. Li Z. Initial searching for the early influence and interfere about the regulating function of the blood-glucose affected by chlorpromazine and risperidal. Journal of Health and Well Being 2007;4:18-20.
120. Pappas D, Konitsiotis S, Liakos A. Risperidone in the treatment of acute schizophrenic episodes. European Neuropsychopharmacology 1997;7:S206.
121. Qu ZW, Chen MD, Gu JQ, Fu WZ, Wang T, Gu LM, et al. Metabolism of the blood-glucose that affected by chlorpromazine or risperidone treatment. Journal of Clinical Psychiatric Medicine [Linchuang Jingshen Yixue Zazhi] 2006;16:68-70.
122. Shi Y, Wang Y, Li R. Effects of risperidone on NEF of eye movements in the first-episode schizophrenia. Journal of Clinical Psychosomatic Diseases 2007;13:487-9.
123. Su YQ. Effects of low dosage risperdal to treat the first attack of schizophrenia. Youjiang Medical Journal 2002;30:380-1.
124. Tian R. Risperidone combined with chlorpromazine in the treatment of insomnia clinical observation of patients with schizophrenia. Journal of Clinical Psychosomatic Diseases 2005;11:151-2.
125. Arvanitis LA, Miller BG. An atypical antipsychotic: results from a multiple fixed dose, placebo-controlled study. European Neuropsychopharmacology 1996;6:148.
126. AstraZeneca. A multicentre, double-blind, randomised trial to compare the effects of seroquel and chlorpromazine in patients with treatment-resistant schizophrenia (5077IL/0054 TRESS). http://www.clinicalstudyresults.org/ (accessed 28 February 2012).
127. AstraZeneca. A multicenter, double-blind, randomized, comparison of quetiapine (seroquel®) and chlorpromazine in the treatment of subjects with treatment-resistant schizophrenia. http://www.clinicalstudyresults.org/ (accessed 28 February 2012).
128. Bai H. Quetiapine and chlorpromazine in the treatment of schizophrenia. Medical Journal of Chinese People's Health 2006;18:1028-9.
129. Cai J, Ji L, Liu X. Clinical effects comparison of quetiapine and chlorpromazine hydrochloride in treatment of female schizophrenia. China Pharmaceuticals 2008;17(21):52-3.
130. Du QX, Yu CF, Zhong W. A clinical comparative analysis of quetiapine and chlorpromazine in treatment of schizophrenia. Medical Journal of Chinese People's Health 2004;16(7):398-9.
131. Jiang K. Quetiapine vs chlorpromazine for schizophrenia – a multi-centre, randomized controlled clinical trial. Proceedings of the 1st Chinese National Conference of Psycho-Neuroscience; 2004 Unknown Dates; Changsha, China. Changsha, China, 2004:106.
132. Li YQ. Comparative analysis of side effects of quetiapine and chlorpromazine in the treatment of schizophrenia. Practical Clinical Medicine 2005;6:26-7.
133. Ma ZW, Li MX, Shi YZ, Wang LH. Quetiapine (35 patients) vs chlorpromazine (34 patients) in treatment of schizophrenia. Chinese Journal of New Drugs and Clinical Remedies 2004;23(5):273-5.
134. Ning Z, Liu S, Jin S. A comparison of cognitive function in first episode schizophrenia treated with seroquel or chlorpromazine. Chinese Journal of Health Psychology 2008;16(2):138-40.
135. Tang Y. Quetiapine and chlorpromazine in the treatment of schizophrenia observed. Chinese Modern Medicine 2004;3(11):14.
136. Tang CG, Wang RC. Comparison of efficacy and safety of quetiapine and chlorpromazine in the treatment of schizophrenia. Medical Journal of Chinese People's Health 2008;20(9):917-8.
137. Wang Y, Li G, Xue JW, Li T. A comparative study of effects of quetiapine and chlorpromazine on the brain blood stream dynamics in the treatment of schizophrenia. Linchuang Jingshen Yixue Zazhi 2007;17(4):255-6.
138. Zhang L. A comparative study of quetiapine and chlorpromazine in the treatment of schizophrenia. Chinese Modern Medicine and Pharmacy 2007;9(2):97-8.
139. Zhong CL, Cui YH. Comparative study of influence of quetiapine on life quality in schizophrenic patients. Journal of Clinical Psychological Medicine 2005;15(2):103-5.
140. Wang L, Song J, Su G. Random comparing research on the treatment of schizophrenia by risperidone and chlorpromazine. Tianjin Pharmacy 1998;10:57-60.
141. Wang LG, Liu Y, Wan H. A comparative trial of the efficacy on olanzapine and chlorpromazine in treatment-resistant schizophrenia. Heath Psychology Journal 2004;12:203-4.
142. Wang T. Study on influence of the short - term therapy by chlorpromazine or risperidal on 2hPG. Journal of Qiqihar Medical College [Qiqihar Yixueyuan Xuebao] 2006;27:1417-8.
143. Xiong Y. Comparison study of childhood schizophrenia treated with risperidone and chlorpromazine. Guizhou Medical Journal 2004;28:697-8.
144. Yu J, Chai M, Chen J. A comparison of cognitive function in schizophrenia treated with risperidone and chlorpromazine. Journal of Clinical Psychological Medicine 2001;11:265-6.
145. Yuan J, Qu WZ. The first use of chlorpromazine and risperidone on glucose metabolism in patients with schizophrenia. Sichuan Mental Health 2006;19:197-9.
146. Zou QL, Fan JH, Chen SQ. A comparative trial on the efficacy of risperidone vs chlorpromazine in the treatment of chronic schizophrenia. Medical Journal of Chinese People's Health 2005;17:153-4.
147. Adams CE, Rathbone J, Thornley B, Clarke M, Borrill J, Wahlbeck K, et al. Chlorpromazine for schizophrenia: a Cochrane systematic review of 50 years of randomised controlled trials. BMC Medicine 2005;3:15. [DOI: 10.1186/1741-7015-3-15]
148. Adams CE, Tharyan P, Coutinho ES, Stroup TS. The schizophrenia drug-treatment paradox: pharmacological treatment based on best possible evidence may be hardest to practise in high-income countries. British Journal of Psychiatry 2006;189:391-2. [PUBMED: 17077426]
149. Adams CE, Awad G, Rathbone J, Thornley B. Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD000284.pub3]
150. Ahmed U, Jones H, Adams CE. Chlorpromazine for psychosis induced aggression or agitation. Cochrane Database of Systematic Reviews 2010, Issue 4. [DOI: 10.1002/14651858.CD007445.pub2]
151. Almerie MQ, Alkhateeb H, Essali A, Matar HE, Rezk E. Cessation of medication for people with schizophrenia already stable on chlorpromazine. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD006329]
152. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200.
153. Andreasen NC. Negative symptoms in schizophrenia. Definition and reliability. Archives of General Psychiatry 1982;39(7):784-8.
154. Andreasen NC. Scale for the Assessment of Positive Symptoms (SANS). Iowa City: University of Iowa, 1984.
155. Anon. Scientific fraud: action needed in China. Lancet 2010;375(9709):94.
156. Arana GW. An overview of side effects caused by typical antipsychotics. Journal of Clinical Psychiatry 2000;61(Suppl 8):5-11.
157. Bian Q, Kato T, Monji A, Hashioka S, Mizoguchi Y, Horikawa H, et al. The effect of atypical antipsychotic drugs, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008;32(1):42-8.
158. Bland RC, Parker JH, Orn H. Prognosis in schizophrenia. Prognostic predictors and outcome. Archives of General Psychiatry 1978;35(1):72-7. [DOI: 10.1001/archpsyc.1978.01770250074007]
159. Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315(7108):600.
160. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'etude des indices d'efficacite]. Therapie 1999;54(4):405-11. [PUBMED: 10667106]
161. Caccia S, Pasina L, Nobili A. New atypical antipsychotic drugs for schizophrenia: iloperidone. Drug Design, Development and Therapy 2010;4:33–48.
162. Chen YF. Chinese classification of mental disorders (CCMD-3): towards integration in international classification. Psychopathology 2002;35(2-3):171-5.
163. Chouinard G, Ross-Chouinard A, Annable L, Jones B. Extrapyramidal Symptom Rating Scale (abstract). Canadian Journal of Neurogical Sciences 1980;7:233.
164. Cincotta SL, Rodefer JS. Emerging role of sertindole in the management of schizophrenia. Neuropsychiatric Disease and Treatment 2010;7:429-41.
165. Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.
166. Deeks JJ, Higgins JPT, Altman DG, on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org 2011.
167. Delay J, Deniker P. The treatment of psychosis in a derivative of the neuroleptic hibernotherapie method [Le traitement des psychoses par une méthode neuroleptique dérivée de l'hibernothérapie]. In: Ossa PC editor(s). CR Congrès des Médicins Aliénistes et Neurologistes de France et des Pays de Langue Française. Paris: Masson, 1952:479.
168. Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623-9.
169. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21(19):2971-80.
170. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington DC: American Psychiatric Association, 1994.
171. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington DC: American Psychiatric Association, 2000.
172. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
173. Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
174. Flanagan JC. Measurement of the quality of life: Current state of the art. Archives of Physical Medicine and Rehabilitation 1982;63(2):56-9.
175. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(1):7-10.
176. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149(9):876-83.
177. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health. DHEW Publication NO (ADM), 1976:124-585.
178. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 1960;23:56-62.
179. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
180. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
181. Higgins JPT, Deeks JJ. Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org 2011.
182. Higgins JPT, Deeks JJ, Altman DG, on behalf of the Cochrane Statistical Methods Group. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org 2011.
183. Honigfeld G, Klett CJ. The nurses' observation scale for inpatient evaluation: a new scale for measuring improvement in chronic schizophrenia. Journal of Clinical Psychology 1965;21:65-71.
184. Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology 2009;146(1):27-30.
185. World Health Organization. F-20. The ICD-10 Classification of Mental and Behavioural Disorders. Geneva: Divison of Mental Health, WHO, 1992:86-109.
186. ICH Expert Working Group. ICH harmonised tripartite guideline: structure and content of clinical study reports. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use 30 November 1995.
187. Janssen PA, Niemegeers CJ, Awouters F, Schellekens KH, Megens AA, Meert TF. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. Journal of Pharmacology and Experimental Therapeutics 1988;244(2):685-93.
188. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.
189. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987;13(2):261-76.
190. Kinon B J, Lieberman JA. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology 1996;124(1-2):2-34. [DOI: 10.1007/BF02245602]
191. Kraeplin E. Dementia Praecox and Paraphrenia. Edinburgh: E&S Livingstone, 1919.
192. Laborit H, Huguenard P. Artificial hibernation by physical and pharmacodynamic means [L'hibernation artificielle par moyens pharmacodynamiques et physiques]. Presse Médicale 1951;59:1329.
193. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale scores. British Journal of Psychiatry 2005;187:366-71. [PUBMED: 16199797]
194. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2-3):231-8. [PUBMED: 15982856]
195. Leucht S, Engel RR, Bäuml J, Davis JM. Is the superior efficacy of new generation antipsychotic drugs an artifact of LOCF?. Schizophrenia Bulletin 2007;33(1):183-91. [PUBMED: 16905632]
196. Leucht C, Kitzmantel M, Chua L, Kane J, Leucht S. Haloperidol versus chlorpromazine for schizophrenia. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD004278.pub2]
197. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373(9657):31-41.
198. Liu X, De Haan S. Chlorpromazine dose for people with schizophrenia. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD007778]
199. Maier W, Buller R, Philipp M, Heuser I. The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. Journal of Affective Disorders 1988;14(1):61-8. [DOI: 10.1016/0165-0327(88)90072-9]
200. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
201. Mathews M, Muzina DJ. Atypical antipsychotics: new drugs, new challenges. Cleveland Clinic Journal of Medicine 2007;74(8):597-606.
202. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiologic Reviews 2008;30:67-76. [DOI: 10.1093/epirev/mxn001]
203. Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 1989;99 Suppl:S18-27. [DOI: 10.1007/BF00442554]
204. Monchi O, Petrides M, Petre V, Worsley K, Dagher A. Wisconsin Card Sorting revisited: distinct neural circuits participating in different stages of the task identified by event-related functional magnetic resonance imaging. The Journal of Neuroscience 2001;21(19):7733-41.
205. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979;134:382-9.
206. Nadal R. Pharmacology of the atypical antipsychotic remoxipride, a dopamine D2 receptor antagonist. CNS Drug Reviews 2001;7(3):265-82.
207. Odejide AO, Ban TA. Psychotropic drug prescription pattern in a developing country (Nigeria). The need for an essential psychotherapeutic drug list. International Pharmacopsychiatry 1982;17(3):163-9.
208. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962;10:799-812.
209. Parrott AC, Hindmarch I. The Leeds Sleep Evaluation Questionnaire in psychopharmacological Investigations - a review. Psychopharmacology 1980;71(2):173-9.
210. Risbood V, Lee JR, Roche-Desilets J, Fuller MA. Lurasidone: an atypical antipsychotic for schizophrenia. Annals of Pharmacotherapy 2012;46(7-8):1033-46.
211. Rossi A, Daneluzzo E, Tomassini A, Struglia F, Cavallaro F, Smeraldi E, et al. The effect of verbalization strategy on wisconsin card sorting test performance in schizophrenic patients receiving classical or atypical antipsychotics. BMC Psychiatry 2006;6:3.
212. Rzewuska M. Sulpiride: the best known atypical, safe neuroleptic drug. Review of literature. Psychiatria Polska 1998;32(5):655-66. [PUBMED: 9921002]
213. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Medicine 2005;2(5):e141. [DOI: 10.1371/journal.pmed.0020141]
214. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Chichester: The Cochrane Collaboration, 2008:359-83.
215. Smith TLL, Carter CW. Asenapine: a novel atypical antipsychotic agent for schizophrenia and bipolar I disorder. Journal of Pharmacy Technology 2010;26:352-61.
216. Sterne JAC, Egger M, Moher D, on behalf of the Cochrane Bias Methods Group. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org 2011.
217. Sullivan M, Karlsson J, Bengtsson C, Furunes B, Lapidus L, Lissner L. The Göteborg Quality of Life Instrument – a psychometric evaluation of assessments of symptoms and well-being among the women in a general population. Scandinavian Journal of Primary Health Care 1993;11(4):267-75.
218. Takahashi N, Terao T, Oga T, Okada M. Comparison of risperidone and mosapramine addition to neuroleptic treatment in chronic schizophrenia. Neuropsychobiology 1999;39(2):81-5.
219. Toren P, Samuel E, Weizman R, Golomb A, Eldar S, Laor N. Emergence of transient compulsive symptoms during treatment with clothiapine. Journal of the American Academy of Child & Adolescent Psychiatry 1995;34(11):1469-72. [DOI: 10.1097/00004583-199511000-00013]
220. Turner T. Chlorpromazine: unlocking psychosis. BMJ (Clinical research ed.) 2007;334 Suppl 1:s7. [PUBMED: 17204765]
221. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):iii-92.
222. World Health Organization. WHO model list of essential medicines. 17th Edition. Geneva: World Health Organization, March 2011.
223. Wechsler D, Holdnack JA, Drozdick LW. Wechsler Memory Scale – Fourth Edition (WMS-IV). San Antonio: Pearson, 2009.
224. Wu T, Li Y, Liu G, Bian Z, Li J, Zhang J, et al. Investigation of authenticity of 'claimed' randomized controlled trials (RCTs) and quality assessment of RCT reports published in China. Proceedings of the 14th Cochrane Colloquium; 2006 October 23-26; Dublin. Dublin, 2006.
225. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.
226. Yorston G, Pinney A. Chlorpromazine equivalents and percentage of British National Formulary maximum recommended dose in patients receiving high-dose antipsychotics. Psychiatric Bulletin 2000;24(4):130-2.
227. Zhang W, Bymaster FPP. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors. Psychopharmacology 1999;141(3):267-78. [DOI: 10.1007/s002130050834]